Earnings ·
Azenta reports $622M FY revenue and issues $648-$660M FY27 guidance
AZTAAzenta, Inc.
Azenta reported full-year fiscal 2026 revenue of $622 million, a 5% increase year over year. The company recorded a net loss from continuing operations of $158 million, driven by a $149 million non-cash goodwill impairment charge and higher operating expenses. Adjusted diluted EPS for the full year was $0.48, down from $0.51 in fiscal 2025. For fiscal 2027, Azenta expects total revenue between $648 million and $660 million, with organic growth of 3% to 5%. The company also announced strategic investments, including a license agreement with Elegen Corp. for gene synthesis technologies and the acquisition of SynPlexity Inc. for up to $25 million in cash. Azenta operates as a provider of life sciences solutions, offering cold-chain sample management and multiomics services.